ArticlemBio2016
Evolutionary History of the Global Emergence of the Escherichia coli Epidemic Clone ST131.
Article in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 227 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
227 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of Pandemic Escherichia coli ST131 Plasmidome Proves Restricted Plasmid-clade Associations.Scientific reports · 2020Pooled it
- Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.Clinical microbiology reviews · 2019Pooled it
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Genomic global epidemiology and evolution ofMicrobial genomics · 2026Article
- Mapping the evolutionary path towards multi-drug resistance in the pandemicMicrobial genomics · 2026Article
- Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Molecular characterization of extended-spectrum β-lactamases-producing Escherichia coli isolated from patients with bacteremia.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2026Article
- Genomic Characterization of Selected Multidrug-ResistantAnimals : an open access journal from MDPI · 2026Article
- Unmasking pathogen traits for chronic colonization in neurogenic bladder.Cell reports · 2026Article
- Spread of extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) in the community living spaces of patients identified as ESBL-E carriers: impact of the housing density in an African context.Tropical medicine and health · 2026Article
- Genomic characterization of extended-spectrum β-Lactamases (ESBLs)-producing Escherichia coli recovered from bloodstream infections in China.BMC microbiology · 2026Article
- Pathogenomics of multidrug-resistant Escherichia coli from bloodstream infections in South Africa.BMC medical genomics · 2026Article
- Plasmid-Driven Resistome Diversity in 9700Antibiotics (Basel, Switzerland) · 2026Article
- Community-associated quinolone-resistant and extended-spectrum beta-lactamase-producingmSystems · 2026Article
- Prevalence of Candidate Vaccine Targets and Genomic Features of Pediatric Invasive Streptococcus Agalactiae in Japan.The Journal of infectious diseases · 2026Article
- Exploration of the genomic diversity of third-generation cephalosporin-resistantMicrobial genomics · 2026Article
- Transfer potential of F-like plasmids inISME communications · 2026Article
- Article
- Challenges and considerations for whole-genome-based antimicrobial resistance plasmid investigations.Antimicrobial agents and chemotherapy · 2025Review
- Genomic islands and plasmid borne antimicrobial resistance genes drive the evolution of high-risk, ST-131 uropathogenic E. coli NS30.BMC genomics · 2025Article
167 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
unlabelledEscherichia colisequence type 131 (ST131) has emerged globally as the most predominant extraintestinal pathogenic lineage within this clinically important species, and its association with fluoroquinolone and extended-spectrum cephalosporin resistance impacts significantly on treatment. The evolutionary histories of this lineage, and of important antimicrobial resistance elements within it, remain unclearly defined. This study of the largest worldwide collection (n= 215) of sequenced ST131E. coliisolates to date demonstrates that the clonal expansion of two previously recognized antimicrobial-resistant clades, C1/H30R and C2/H30Rx, started around 25 years ago, consistent with the widespread introduction of fluoroquinolones and extended-spectrum cephalosporins in clinical medicine. These two clades appear to have emerged in the United States, with the expansion of the C2/H30Rx clade driven by the acquisition of ablaCTX-M-15-containing IncFII-like plasmid that has subsequently undergone extensive rearrangement. Several other evolutionary processes influencing the trajectory of this drug-resistant lineage are described, including sporadic acquisitions of CTX-M resistance plasmids and chromosomal integration ofblaCTX-Mwithin subclusters followed by vertical evolution. These processes are also occurring for another family of CTX-M gene variants more recently observed among ST131, theblaCTX-M-14/14-likegroup. The complexity of the evolutionary history of ST131 has important implications for antimicrobial resistance surveillance, epidemiological analysis, and control of emerging clinical lineages ofE. coli These data also highlight the global imperative to reduce specific antibiotic selection pressures and demonstrate the important and varied roles played by plasmids and other mobile genetic elements in the perpetuation of antimicrobial resistance within lineages. IMPORTANCE: Escherichia coli, perennially a major bacterial pathogen, is becoming increasingly difficult to manage due to emerging resistance to all preferred antimicrobials. Resistance is concentrated within specificE. colilineages, such as sequence type 131 (ST131). Clarification of the genetic basis for clonally associated resistance is key to devising intervention strategies. We used high-resolution genomic analysis of a large global collection of ST131 isolates to define the evolutionary history of extended-spectrum beta-lactamase production in ST131. We documented diverse contributory genetic processes, including stable chromosomal integrations of resistance genes, persistence and evolution of mobile resistance elements within sublineages, and sporadic acquisition of different resistance elements. Both global distribution and regional segregation were evident. The diversity of resistance element acquisition and propagation within ST131 indicates a need for control and surveillance strategies that target both bacterial strains and mobile genetic elements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.